MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Evolocumab 1 endocrinologydiseasesdrugs
atorvastatin 1 endocrinologydiseasesdrugs
ezetimibe 4 endocrinologydiseasesdrugs
rosuvastatin 1 endocrinologydiseasesdrugs

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Evolocumab 15752 PCSK9 profoundly reduce LDL-C in FH patients [[78]–[82]]{Sahebkar, 2013 #48; Sahebkar, 2013 #49}. Evolocumab (Repatha®) and alirocumab (Praluent®) are now approved by regulatory authorities in the USA, Europe,
atorvastatin 3635 untreated LDL-C > 500 mg/dL and at only minimal to moderate residual LDLR activity, even high doses of atorvastatin or rosuvastatin reduce mean LDL-C by only 22–25% [[12], [13]], and ezetimibe achieves an additional
ezetimibe 2315 arterial wall, thus accelerating atherosclerosis and the risk of premature CVD [[6], [7]].Statins, ezetimibe , bile acid sequestrants, and more recently PCSK9 inhibitors are the main therapeutic drugs for the treatment
ezetimibe 2948 reduction can also be achieved by regular LDL apheresis which mechanically removes LDL. Statins and ezetimibe are the most commonly used cholesterol-lowering drugs and are now generically available at low cost
ezetimibe 3717 even high doses of atorvastatin or rosuvastatin reduce mean LDL-C by only 22–25% [[12], [13]], and ezetimibe achieves an additional 20% reduction [[14]], thus few, if any, HoFH patients can reach anywhere near
ezetimibe 16331 LDL-C reductions resulted in further reductions in CVD when added to existing statin with or without ezetimibe therapy [[83], [84]]. The CVD benefit has recently been confirmed in the Further Cardiovascular Outcomes
rosuvastatin 3651 LDL-C > 500 mg/dL and at only minimal to moderate residual LDLR activity, even high doses of atorvastatin or rosuvastatin reduce mean LDL-C by only 22–25% [[12], [13]], and ezetimibe achieves an additional 20% reduction
Select Disease Character Offset Disease Term Instance

You must be authorized to submit a review.